Skip to content
Profile icon

Dr Kamal Gadalla


School of Science & Technology


DR Kamal Gadalla is a clinician scientist and he is part of the pharmacology teaching team at both undergraduate and postgraduate levels. His research focuses on developing safe and effective gene therapies for the treatment of neurological disorders.

Career overview

Dr Kamal Gadalla joined NTU in 2023. He got a medical degree from Tanta University and was trained as a physician/surgeon prior to taking an academic post in pharmacology at the Faculty of Medicine, Tanta University. Then he got a PhD scholarship to study gene therapy and translation neuroscience at the Institute of Neuroscience and Psychology, Glasgow university where he published the first proof-of-concept paper showing the potential of gene therapy in treating neurodevelopmental disorders. After PhD completion, he completed his pioneering research in gene therapy as a post-Doc researcher at the University of Glasgow and as a Research fellow at the Centre For Discovery Brain Sciences at the University of Edinburgh where he established a vector core production facility and co-supervised several gene therapy projects in Rett syndrome, Fragile X syndrome, SynGap1 haploinsufficiency, and PTEN hamartoma tumor syndrome.

Research areas

Dr Kamal research focuses on developing safe and effective gene therapies for the treatment of neurological disorders. He was the first to report the therapeutic benefit of gene therapy in mice modelling Rett syndrome and helped in developing several gene therapy products from bench to clinics in what is considered as the first gene therapy clinical trial for neurodevelopmental disorders. He is also testing similar approaches to treat other neurodevelopmental and neurodegenerative disorders.

External activity

Journal reviewer

  • Member of editorial board of the World Journal  of Methodology
  • Review editor , Frontier in Molecular Neuroscience

Ad hoc Grant reviewer

  • Ormond Street Hospital Charity
  • Medical Research Council
  • French National Research Agency


  1. Samantha Powers, Shibi Likhite, Kamal K Gadalla, Carlos J Miranda, Amy J Huffenberger, Cassandra Dennys, Kevin D Foust, Pablo Morales, Christopher R Pierson, Federica Rinaldi, Stephanie Perry, Brad Bolon, Nicolas Wein, Stuart Cobb, Brian K Kaspar, Kathrin Meye (2023). Novel MeCP2 Gene Therapy is Effective in a Multicenter Study using Two Mouse Models of Rett Syndrome and is Safe in Non-human Primates. Molecular Therapy,
  2. Stephanie A Zlatic, Duc Duong, Kamal KE Gadalla, Brenda Murage, Lingyan Ping, Ruth Shah, James J Fink, Omar Khwaja, Lindsay C Swanson, Mustafa Sahin, Sruti Rayaprolu, Prateek Kumar, Srikant Rangaraju, Adrian Bird, Daniel Tarquinio, Randall Carpenter, Stuart Cobb, Victor Faundez (2022). Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome. Iscience 25 (9)
  3. María Velasco‐Estevez, Kamal KE Gadalla, Núria Liñan‐Barba, Stuart Cobb, Kumlesh K Dev, Graham K Sheridan (2019). Inhibition of Piezo1 attenuates demyelination in the central nervous system. Glia 68 (2), 356-375
  4. Rebekah Tillotson, Jim Selfridge, Martha V Koerner, Kamal KE Gadalla, Jacky Guy, Dina De Sousa, Ralph D Hector, Stuart R Cobb, Adrian Bird (2017). Radically truncated MeCP2 rescues Rett syndrome-like neurological defects. Nature 550 (7676), 398.
  5. NG Bahey, Kamal KE Gadalla, R McGonigal, MES Bailey, JM Edgar, SR Cobb (2017). Reduced axonal diameter of peripheral nerve fibers in a mouse model of Rett syndrome. Neuroscience 358, 261-268.
  6. Kamal KE Gadalla, Thishnapha Vudhironarit, Ralph D Hector, Sarah Sinnett, Noha G Bahey, Mark ES Bailey, Steven J Gray, Stuart R Cobb (2017). Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome. Molecular Therapy-Methods & Clinical Development 5, 180-190.
  7. Sarah E Sinnett, Ralph D Hector, Kamal KE Gadalla, Clifford Heindel, Daphne Chen, Violeta Zaric, Mark ES Bailey, Stuart R Cobb, Steven J Gray (2017). Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery. Molecular Therapy-Methods & Clinical Development 5, 106-115.
  8. Kamal KE Gadalla, Paul D Ross, Ralph Hector, Noha G Bahey, Mark E.S. Bailey, and Stuart R. Cobb (2015). Gene therapy for Rett syndrome: prospects and challenges. the Journal of Future Neurology. Future Neurology 10 (5), 467-484.
  9. Kamal KE Gadalla, PD Ross, JS Riddell, MES Bailey, SR Cobb (2014). Gait Analysis in a Mecp2 Knockout Mouse Model of Rett Syndrome Reveals Early-Onset and Progressive Motor Deficits. PloS one 9 (11), e112889.
  10. Kamal KE Gadalla, Bailey ME, Spike RC, Ross PD, Woodard KT, Kalburgi SN, Bachaboina L, Deng JV, West AE, Samulski RJ, Gray SJ, Cobb SR (2013) Improved Survival and Reduced Phenotypic Severity Following AAV9/MECP2 Gene Transfer to Neonatal and Juvenile Male Mecp2 Knockout Mice. Mol Ther. doi:10.1038/mt.2012.200.
  11. Kamal KE Gadalla, MES Bailey, SR Cobb (2011). MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochemical Journal 439 (1), 1-14
  12. Noha Gamal Bahey, Hekmat Osman Abd Elaziz, Kamal KE Gadalla (2015). Toxic effect of aflatoxin B1 and the role of recovery on the rat cerebral cortex and hippocampus. Tissue and Cell 47 (6), 559-566.

See all of Dr Kamal Gadalla's publications...

Press expertise